U6 small nuclear RNA (snRNA) is the most highly conserved of the five spliceosomal snRNAs that participate in nuclear mRNA splicing. The proposal that U6 snRNA plays a key catalytic role in splicing [D. Brow and C.
Introns are removed from eukaryotic mRNA precursors by a large, structurally dynamic ribonucleoprotein (RNP) complex known as the spliceosome. The spliceosome contains the Ul, U2, U4/U6, and U5 small nuclear RNP (snRNP) particles, numerous auxiliary protein factors, and the mRNA precursor (14-17, 32, 45, 55) . Each snRNP consists of one small nuclear RNA (snRNA) (except the U4/U6 snRNP, which contains two RNAs extensively base paired to each other [3, 18, 42, 52] ), a common set of proteins known as Sm antigens, and several other proteins unique to each snRNP (28, 29) . The assembly of the spliceosome is an ATP-dependent process involving stepwise binding of snRNPs and protein factors to the mRNA precursor. The intron is removed by two sequential transesterification reactions. In the first step, the 2' hydroxyl of the branch site attacks the 5' splice site, releasing the 5' exon and forming a 2',5'-lariat intermediate; in the second step, the 3' hydroxyl of the 5' exon attacks the 3' splice site, ligating the exons and releasing the intron as a lariat.
Ordered assembly of the spliceosome on the mRNA precursor involves RNA-RNA, RNA-protein, and proteinprotein interactions. Among the RNA-RNA interactions, Ul snRNP base pairs initially with the 5' splice site (26, 44, 48, 71) and later, at least in some organisms, with the 3' splice site (41, 47) . U2 snRNP interacts with the 3' region of the intron initially through a number of protein factors (reviewed in references 13 and 46) and later by base pairing with the branch site (35, 38, 64, 70) . Lastly, U5 and the U4/U6 snRNPs join the spliceosome as a triple snRNP complex (1, 2, 7, 24, 25, 27) and U5 snRNP base pairs with 5' and 3' exon sequences (36, 37, 60, 67) . The dual interactions of Ul and US snRNPs at both the 5' and 3' splice sites (but see * Corresponding author. reference 47) have been incorporated into a structural model involving branch migration within a Holliday intermediate (54) . An additional base pairing interaction between U2 and U6 snRNP (9, 10, 12, 19, 61, (63) (64) (65) , now designated helix II (31) , plays a role in spliceosome assembly (63) , but a subsequent role in the first or second step of splicing is also possible.
There are compelling reasons to believe that U6 snRNA plays a catalytic role in mRNA splicing. U6 (along with U2) is the most highly conserved of the spliceosomal snRNAs (31) . Extensive base pairing between U4 and U6 is unwound, and U4 dissociates from the spliceosome before the first transesterification (5, 7, 25, 39, 63, 68) , as expected if U4 prevents U6 from adopting a catalytically inactive conformation or a prematurely active conformation (4, 16) . Point mutations (10, 30, 31) or thiophosphate substitutions (11) in two invariant sequences of U6 (47-ACAGAGA-53 and 59-AGC-61) can selectively block either the first or second step of splicing in Saccharomyces cerevisiae, as do mutations in the corresponding sequences ofXenopus U6 (59). These two invariant sequences are juxtaposed with the mRNA precursor by a novel U2-U6 interaction that is mutually exclusive with the U4-U6 interaction (31) . Additional, if less compelling, arguments can also be adduced in favor of a catalytic role for U6. U6 snRNA precursors in several other yeasts, including Schizosaccharomyces pombe, contain introns whose locations within highly conserved and mutationally sensitive sequences of U6 suggest acquisition by reverse splicing (57) . Certain conserved features of U6 snRNA bear a remarkable resemblance to the autocatalytic core of the negative strand of tobacco ring spot virus (58) . And finally, both mechanistic and structural similarities between nuclear mRNA splicing and group II autocatalytic splicing suggest that nuclear mRNA splicing is fundamentally an RNAcatalyzed reaction (6, 22, 23, 31, 49, 50, 62) .
DAITA AND WEINER
Despite the overall similarity of mRNA splicing in S. cerevisiae and mammals, there are significant differences. For example, the 5' splice site and branch sites are nearly invariant in S. cerevisiae but adhere to a loose consensus in metazoans (15, 33) . On the other hand, the base pairing interaction between U2 and U6 known as helix II (31) may be less flexible in mammals (9, 12, 19, (63) (64) (65) (66) than in S. cerevisiae (10, 12, 30, 51) . We therefore decided to test experimentally whether mutations in the phylogenetically invariant ACAGAGA and AGC sequences of human U6 would block the first or second step of splicing selectively as did the corresponding mutations in S. cerevisiae (10, 30) .
We introduced all possible second-site point mutations into the homologous sequences 47-ACAGAGA-53 and 59-AGC-61 of a human U6 suppressor gene (U6su+b) and assayed these mutants in vivo with the double suppression assay previously developed to examine potential base pairing between U2 and U6 (9) . Our data indicate that both the ACAGAGA and AGC sequences are less sensitive to mutation in human cells than in S. cerevisiae. These and other data are discussed in the context of current models for snRNA function.
MATERIALS AND METHODS All procedures have been described previously (9) except second-site point mutations which were introduced in positions 41-ACAGAGA-47 and 53-AGC-55 of the human U6 suppressor gene (U6su+b) in M13mpl9 by using doped DNA oligonucleotides corresponding to the U6 coding strand. For each site to be mutated, a 25-mer was synthesized with 12-bp clamps flanking a central doped nucleotide (33% of each of the three other nucleotides). Four mutants not obtained by this procedure (A45G, G46T, A47G, and A53G [where A45G denotes mutation of A-45 to G]) were generated by using analogous undoped DNA oligonucleotides. After mutagenesis, the EcoRI-HindIII fragment spanning each mutant U6 gene was recloned into pUC13 and used for transfection of human 293 cells as described previously (9) .
RESULTS
Mammalian spliceosomal snRNAs are encoded by multigene families (8) , necessitating the use of suppressor snRNAs for genetic analysis of spliceosomal snRNA structure and function in vivo. We previously developed a double suppression assay to examine the potential for a U2-U6 base pairing interaction (9, 19, 65) in a region now known as helix II (31) . In this assay (shown schematically in Fig. 1 ), we measure alternative 3' splicing of a specially engineered mRNA precursor derived from the first intron of the human r-globin gene (72) . This precursor, designated 10,g,P110, has two branch sites (normal and cryptic) and two 3' splice sites (13110 and normal); the normal branch site is mutated from the wild-type CACUGAC to the maximally efficient UACUAAC (70) , and the second 3' splice site is generated by introduction of the 1"1 thalassemia mutation, a G to A transition 21 nucleotides upstream from the normal 3' splice site.
In the absence of a suppressor U2 snRNA, the more efficient normal branch site is used preferentially, and splicing is directed to the 110 3' splice site because the proximal AG is favored (53, 73) . In the presence of a suppressor U2 snRNA (designated U2-35C) with improved complementarity to the cryptic branch site, the cryptic branch site is used preferentially, and splicing is directed to the normal 3' splice site because the cryptic branch site is prohibitively close to the 1110 3' splice site. Here, we use a suppressor U2 snRNA (designated U2b) with an additional multiple mutation in nucleotides 3 to 6 which renders it inactive except in the presence of a suppressor U6 snRNA (designated U6su+b) with a compensatory multiple mutation that restores U2/U6 helix II (9) . This assay enabled us to examine the effect of second-site mutations in the suppressor U6su+b on splicing of the 10,g,01310 precursor.
We chose to target the phylogenetically conserved 41-ACAGAGA-47 and 51-AGC-53 sequences of human U6 (boldface in Fig. 1 ), generating all three nucleotide substitutions at each position and testing the effect of these mutations in vivo by using the double suppression assay in human 293 cells. The results of the assay are presented in Fig. 2A (41-ACAGAGA-47) and B (53-AGC-55). Figure 3 summarizes and compares the results with those obtained for yeast U6 in vivo (30, 31) and in vitro (10) . Controls were included in each experiment to validate the double suppression assay: the branch site mutation in the 10,g,0110 precursor is efficiently suppressed by the compensatory base change in U2-35C (Fig. 2, lanes 1) , the second-site multiple mutation in the 5' end of U2b abolishes suppression (lanes 2), and a compensatory multiple mutation in the 3' end of U6su+b restores suppression by U2b (lanes 3). Note also that total cytoplasmic RNA is being assayed (9, 72) ; although some snRNAs are extracted (20, 69) , nuclear mRNA precursors are unlikely to be extracted reliably or quantitatively and conclusions cannot be drawn from the precursor signal in Fig. 2 .
Of the 30 second-site mutations examined in U6su+b, a (Fig. 2, lanes 2 , and also lanes pUC in Fig. la and 2a of reference 9 ). Not shown are three substitutions with the a-phosphorothioate derivative of C which partially (G46C) or completely (G44C) block the first step or completely block the second step (A53C) of splicing (11) . effects in human cells and S. cerevisiae (G54C, G54U, G55U), three had no detectable effect in human cells but partially or completely blocked step 2 in S. cerevisiae in vitro or were lethal or temperature sensitive (A53G, A53C, A53U), and three inhibited more in S. cerevisiae than in human cells (G54A, C55A, C55G) if we assume (on the basis of the full set of data for the ACAGAGA sequence) that for S. cerevisiae .80% splicing efficiency in vitro usually indicates a lethal or temperature-sensitive phenotype in vivo ( Fig. 2B and 3) .
The inhibition of U6 function(s) by mutations in the ACAGAGA and AGC sequences is unlikely to be caused by low expression or instability of the mutant U6 snRNAs. By using a primer extension assay that distinguishes U6su+b and its derivatives from endogenous U6 (9), we found that all second-site mutants of U6su+b that were inactive in splicing (Fig. 2) were expressed at least as well as the active C55A mutant (Fig. 4) .
DISCUSSION
We tested the effect on human mRNA splicing of point mutations in two phylogenetically invariant sequences of U6 snRNA, 41-ACAGAGA-47 and 53-AGC-55, by using the in vivo double suppression assay developed earlier (9) . These sequences have previously been the subject of extensive analysis in the yeast Saccharomyces cerevisiae by point mutations in vitro (10) and in vivo (30, 31) as well as phosphorothioate substitution in vitro (11) . A number of multiple mutations had also been examined in Xenopus laevis oocytes (59) . Although many mutations in these phylogenetically invariant sequences had similar effects in human cells and S. cerevisiae, we were surprised to find that both sequences appeared to be more tolerant of mutation in human cells than in S. cerevisiae (Fig. 3) Fig. 2 were subjected to a primer extension assay with ddTTP and a primer complementary to U6 nucleotides 96 to 106 as described previously (9) . With the exception of C55A, all U6 mutants assayed here abolished splicing in Fig. 2 . C55A was included as a positive control to determine the level of U6su+b expression required for splicing of the 10,g,3110 mRNA precursor. Expression of A41C, A43C, and A43U was reanalyzed and found to be comparable with that of other ACAGAGA mutants (data not shown).
in S. cerevisiae. Mutations in the AGC sequence are more difficult to compare because four of the nine possible mutations have not been assayed in S. cerevisiae in vivo; however, a provisional comparison can be made if we assume, on the basis of the essentially complete set of data for the ACAGAGA sequence (Fig. 3) , that an in vitro splicing efficiency of <80% in S. cerevisiae is very likely to indicate a lethal or temperature-sensitive phenotype in vivo. Of nine mutations in the AGC sequence, three appear to have similar effects in human cells and S. cerevisiae (G54C, G54U, and C55U), three had no detectable effect in human cells but partially or completely blocked step 2 in S. cerevisiae in vitro (A53G, A53C, and A53U), and three appeared to be more inhibitory in S. cerevisiae than in human cells (G54A, C55A, and C55G). In fact, among the 30 possible mutations (21 in ACAGAGA and 9 in AGC), there are only two instances in which U6 appears to be less tolerant of mutation in human cells than in S. cerevisiae: A41U and G44C inhibit or abolish splicing in human cells in vivo but are wild type in S. cerevisiae; however, G44C is also the most obvious discrepancy between the yeast in vivo and in vitro assays, being the only mutation that inhibits splicing >50% in vitro while still exhibiting a wild-type phenotype in vivo (also see below).
U6 might appear to be more tolerant of mutation in human cells than in S. cerevisiae because the human assay system is less stringent. We examined the effect of mutations in human U6 on splicing of a single mRNA precursor in a transient expression assay, and any effect of these mutations on other mRNA precursors or on cell viability would escape detection. In contrast, the yeast in vivo assay tests directly for cell viability and presumably requires efficient splicing of most if not all essential intron-containing mRNA precursors. However, this is unlikely to explain why U6 appears to be more tolerant of mutation in human cells than in S. cerevisiae, because the yeast in vivo and in vitro assays correlate remarkably well in spite of the fact that the in vitro assay (like the human in vivo assay) examines splicing of a single mRNA and does not require cell viability. In fact, with the sole exception of G44C, all mutations in yeast U6 that inhibit in vitro splicing by >20% also have a detectable phenotype in vivo (10, 30, 31) . This strong correlation suggests that most of the lethal and temperature-sensitive phenotypes of yeast U6 mutants are caused by a general rather than an allele-specific splicing defect (10, 30, 31) and thus that comparison of our results with those obtained in S. cerevisiae is likely to be informative.
Alternatively, human U6 might appear to be more tolerant of mutation because our assay is, for technical reasons, less sensitive than the yeast assays. We cannot detect low levels (<20%) of U6 activity, because the normal 3' splice site continues to be used even in the absence of active suppressor U2 (compare lanes 2 and 3 in Fig. 2A and B) . This would tend to obscure the phenotype of mutations which severely inhibit but do not abolish splicing, such as the yeast equivalents of C42G, G54C, and G54U (Fig. 3) . Also, although our extraction protocol provides good yields of cytoplasmic RNA without contaminating nuclear DNA (9, 72) , the protocol is unlikely to extract nuclear mRNA precursors. We therefore cannot detect a partial first-or second-step block unless it substantially affects the overall rate of splicing, and phenotypes such as those of the yeast equivalents of A53G and A53C in vitro (Fig. 3) would consequently escape our notice.
A third possibility is that human U6 might appear to be more tolerant of mutation because the ACAGAG and AGC sequences, or certain nucleotides within these sequences, participate in steps that are rate limiting in S. cerevisiae but not in human cells or because the mammalian system is able to rely on redundant RNA-RNA, RNA-protein, or proteinprotein interactions-at least in these particular instances. There is already considerable evidence for redundant RNA-RNA, RNA-protein, and protein-protein interactions in mRNA splicing. Ul can base pair with both the 5' splice site and the invariant AG of the 3' splice site in S. pombe (41) but not in S. cerevisiae (47) . Base pairing between U2 and the branch site is required for some introns but may be nearly dispensable for others (64, 72) . Formation of helix II (31) between the 5' end of U2 and the 3' end of U6 is more important for some introns than for others (9, 19, 65, 66) . A strong polypyrimidine tract can circumvent the requirement for a 3' AG in the first step of splicing (40, 53) , a weak polypyrimidine tract potentiates communication across the exon between 3' and 5' splice sites (21) , and a strong polypyrimidine tract can compensate for a weak branch site or vice versa (34, 43) . Taken together, this kind of evidence for evolutionary and mechanistic flexibility in early (5' and 3' splice site choice), middle (branch site selection), and late events of splicing (recognition of the 3' AG) suggests that the catalytically active structure of the spliceosome may be achieved by differential contributions from many potential interactions, although the actual chemistry of the transesterification reaction may be the same in each case.
The most dramatic examples of mutations that have strong effects in S. cerevisiae but appear to be tolerated in human cells are A41C, C42G, C42U, A45U, and A53U (A53U is also tolerated in the Xenopus oocyte assay [59] ); the yeast equivalents of A45U and A53U are completely blocked at the second step of in vitro splicing, while the equivalents of C42G and C42U splice at < 10% efficiency. The ability of the A45U and A53U mutations to selectively block the second step of splicing in S. cerevisiae has been invoked as evidence for direct participation of these residues in the second chemical step of splicing (10, 30) ; however, U6 function appears unaffected by either mutation in human cells or by A53U in Xenopus cells (59) . Although these discrepancies could be explained-as discussed above-by the differing stringencies or sensitivities of the assays, by different ratelimiting steps, or by redundant interactions within the spliceosome, another possibility is that C-42, A-45, and A-53 are not part of a phylogenetically conserved catalytic site. For example, these residues might instead participate in building the structural scaffold required to position catalytically active Mg2e ions within a metalloribozyme (56) . The degree of dependence on A-45 and A-53 observed in different systems might then reflect the extent to which this particular catalytically active structure could be achieved by making compensatory adjustments elsewhere in the RNA and/or protein scaffold.
